Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.310
-0.060 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
2.329
+0.018 (0.80%)
After-hours: Apr 28, 2026, 5:14 PM EDT
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$141,191
Profits / Employee
-$687,679
Market Cap
18.54M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Cocrystal Pharma | 10 |
| Genenta Science | 9 |
LPCN News
- 22 days ago - What's Going On With Lipocine Stock On Monday? - Benzinga
- 22 days ago - Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 26 days ago - Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Benzinga
- 26 days ago - Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - PRNewsWire
- 7 weeks ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire
- 2 months ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire